
Ibudilast decreases progression of brain atrophy in progressive multiple sclerosis
A Phase II clinical trial of ibudilast has revealed that the drug decreases progression of brain atrophy in patients with progressive multiple sclerosis.
A Phase II clinical trial of ibudilast has revealed that the drug decreases progression of brain atrophy in patients with progressive multiple sclerosis.
Robert Fox chats to Lauren Pulling about ibudilast in progressive MS, including the current landscape and potential treatment regimens.